NCT06936397Recruiting
Cognitive Remediation Therapy for Schizophrenia: Effects on EEG and Emotional Regulation
A Randomized Controlled EEG-GSR Study on the Effects of Cognitive Remediation Therapy on Neurophysiological and Emotional Regulation Markers in Schizophrenia
Source: ClinicalTrials.gov · Last updated 20 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to determine whether Cognitive Remediation Therapy (CRT) can improve attention, memory, and emotional regulation in people with schizophrenia. CRT is a structured program that includes exercises to strengthen cognitive skills such as problem-solving, working memory, and emotion regulation. The study will recruit 60 participants: 30 individuals with schizophrenia and 30 healthy individuals of similar age and gender. Those with schizophrenia will be randomly assigned to either receive CRT or be placed on a waitlist without therapy. All participants will undergo non-invasive brain activity (EEG) and emotional response (GSR) recordings before and after the therapy. The study's main question is: Does participating in a 12-week CRT program improve brain-based markers of attention and emotional regulation in people with schizophrenia? Additional tests, such as memory and emotion recognition tasks and self-report questionnaires, will help assess changes in thinking skills and emotional well-being. The study may help better understand how CRT affects both brain function and quality of life in schizophrenia.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 13 Apr 2025
- Start date
- 15 Mar 2025
- Primary completion date
- 15 Aug 2025
- Lead sponsor
- Beykoz University
- Diseases
- Schizophrenia
- NCT number
- NCT06936397
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 15 Mar 2025 to the primary completion date, 15 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of benzodiazepines or medications that significantly affect cognitive function
Other illness
- Current or past substance use disorder (within the past year)
- Comorbid neurological illness (e.g., epilepsy, traumatic brain injury)
Other
- Intellectual disability or MoCA score \< 20
- Visual or hearing impairments that could interfere with task performance
- Participation in a psychological intervention in the last 3 months
Who the study is looking for
- Diagnosed with schizophrenia according to DSM-5 criteria
- Age between 18 and 55 years
- Clinically stable (no hospitalization or medication change within 1 month)
- Minimum primary school education
- Able to provide informed consent
- Right-handed (for EEG protocol consistency)
- No history of psychiatric or neurological disorders
- Age- and gender-matched to schizophrenia group
- No current medication affecting CNS
- Able to provide informed consent
- Right-handed
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beykoz University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Recruiting |
Related publications
- Neurophysiological and autonomic effects of Cognitive Remediation Therapy in schizophrenia: a randomized controlled EEG-GSR study.BMC Psychiatry · 2026 · PMID 42625165
This page is information, not medical advice. Discuss any trial with your doctor.